ORION PHARMA A/S: Financial statements 2020
CVR: 20601116
Source: annual report 2020, Danish Business Authority
01/01/2020 – 31/12/2020
ORION PHARMA A/S (CVR 20601116) has filed annual accounts for 2020. In 2020, the company reported revenue of DKK 282,867,433 and a net result of DKK 6,315,388 compared with DKK 16,907,454 the year before. That is an increase of 0.7% compared with the year before. The profit margin was 2.2%. Equity in the 2020 report amounted to DKK 51,410,267. The solvency ratio was 54.7%. The company had 20 employees in the financial year.
- Revenue
- DKK 282,867,433
- Gross Profit
- DKK 25,468,365
- Profit/Loss
- DKK 6,315,388
- Equity
- DKK 51,410,267
- Total Assets
- DKK 93,919,456
- Employees
- 20
Development
| Year | Revenue | Gross Profit | Profit/Loss | Equity | Employees |
|---|---|---|---|---|---|
| 2020 | 282.9 mio. | 25.5 mio. | 6.3 mio. | 51.4 mio. | 20 |
| 2019 | 280.9 mio. | 43 mio. | 16.9 mio. | 57.6 mio. | 24 |
| 2018 | 247.1 mio. | 51 mio. | 20.5 mio. | 50.7 mio. | 28 |
| 2017 | 327.7 mio. | 73 mio. | 37.8 mio. | 95.2 mio. | 29 |
| 2016 | 373.7 mio. | 101 mio. | 56.7 mio. | 97.3 mio. | 29 |
Official annual report
How creditworthy is ORION PHARMA A/S?
See the CDS score and get a full credit report with recommended credit limit and payment terms.
Read about the CDS scoreEvents in 2020
ORION PHARMA A/S has published its annual report for 2019. Revenue came to DKK 280,861,600, and the net result was DKK 16,907,454.
About ORION PHARMA A/S
ORION PHARMA A/S is a Danish company of the type Aktieselskab based in København S, founded in 1953. The company is registered under the industry Engroshandel med medicinalvarer og sygeplejeartikler. The company was previously named ERCOPHARM A/S. The management consists of Jesper Otto Qvist-Pedersen. The board consists of Satu Maarit Ahomäki (chair), Mikko Tapani Kemppainen and René Kristian Lindell. The company is owned by Orion Corporation. The company has 14 employees (2026). In 2025, the company reported revenue of DKK 329,561,856 and a net result of DKK 10,525,947 compared with DKK 10,899,639 the year before. Equity in the 2025 report amounted to DKK 32,510,625.